Our review of the literature shows that while clinical trials of CD47 monoclonal antibodies are more often registered for solid tumors, there are very few such trials specifically targeting gastrointestinal tumors, and these are mainly conducted in combination with other drugs to compare efficacy against standard treatments (e.g., NCT05002127, currently recruiting) (212). This evidence concerns the gene CD47 and digestive system neoplasm.